Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mirati Therapeutics, Inc. (MRTX : NSDQ)

• Company Description    Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors. Number of Employees: 593

• Price / Volume Information    Yesterday's Closing Price: $37.01 Daily Weekly Monthly 20 Day Moving Average: 1,021,168 shares Shares Outstanding: 58.19 (millions) Market Capitalization: $2,153.50 (millions) Beta: 1.02 52 Week High: $101.30 52 Week Low: $35.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.77% -20.89% 12 Week -9.18% -15.69% Year To Date -18.32% -25.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3545 CRAY COURT - SAN DIEGO,CA 92121 USA ph: 858-332-3410 fax: - ir@mirati.com http://www.mirati.com

• General Corporate Information    Officers David D. Meek - Chief Executive Officer Faheem Hasnain - Chairman Laurie D. Stelzer - Chief Financial Officer Aaron Davis - Director Craig Johnson - Director Peer Information Mirati Therapeutics, Inc. (CORR.) Mirati Therapeutics, Inc. (RSPI) Mirati Therapeutics, Inc. (CGXP) Mirati Therapeutics, Inc. (BGEN) Mirati Therapeutics, Inc. (GTBP) Mirati Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 60468T105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/02/23 Share - Related Items Shares Outstanding: 58.19 Most Recent Split Date: 7.00 (0.02:1) Beta: 1.02 Market Capitalization: $2,153.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-3.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-12.55 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/02/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.49 Price/Cash Flow: - Price / Sales: 113.98 EPS Growth vs. Year Ago Period: 6.47% vs. Previous Quarter: 9.40% Sales Growth vs. Year Ago Period: 910.86% vs. Previous Quarter: 667.34% ROE 03/31/23 - -71.90 12/31/22 - -66.05 09/30/22 - -60.40 ROA 03/31/23 - -61.18 12/31/22 - -56.92 09/30/22 - -52.78 Current Ratio 03/31/23 - 7.54 12/31/22 - 6.95 09/30/22 - 9.65 Quick Ratio 03/31/23 - 7.51 12/31/22 - 6.94 09/30/22 - 9.65 Operating Margin 03/31/23 - -3,901.06 12/31/22 - -5,957.44 09/30/22 - -6,253.81 Net Margin 03/31/23 - -3,901.06 12/31/22 - -5,957.44 09/30/22 - -6,253.81 Pre-Tax Margin 03/31/23 - -3,898.38 12/31/22 - -5,953.35 09/30/22 - -6,251.66 Book Value 03/31/23 - 14.82 12/31/22 - 17.31 09/30/22 - 20.30 Inventory Turnover 03/31/23 - 0.83 12/31/22 - 0.79 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©